European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
Status:
Recruiting
Trial end date:
2035-01-01
Target enrollment:
Participant gender:
Summary
The hereditary type IV collagen disease Alport syndrome inevitably leads to end-stage renal
disease. Currently there are no therapies known to improve outcome. Our non-interventional,
observational study investigates, if medications such as ACE-inhibitors can (1) delay time to
dialysis and (2) improve life-expectancy within three generations of Alport-families in
Europe.
Details
Lead Sponsor:
University Hospital Goettingen
Collaborators:
Alport Selbsthilfe e.V. Association pour l'Information et la Recherche sur les Maladies Rénales Génétiques (AIRG) Deutsche Gesellschaft für Nephrologie Gesellschaft für Pädiatrische Nephrologie KfH Foundation Preventive Medicine Society for Pediatric Nephrology (Germany)